undamentalytics Newsletter
Sign in

Avalo Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Avalo Therapeutics, Inc. had total assets of $116m, total liabilities of $33.4m and shareholders' equity of $83.0m. It held $15.9m in cash against $0 of debt: net cash of $15.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents2152114195513713516
Receivables———————0———
Inventory—00000000——
Total current assets2261122182662168139105
Goodwill—0121414141414111111
Total assets22643703644803321151116
Accounts payable11112333000
Deferred revenue (current)——0———000——
Total current liabilities641126121520225713
Short-term debt3201———————
Long-term debt20014—033130——
Total debt620151503319000
Total liabilities96154915195744141833
Shareholders' equity1302821212523−11713383
Net debt (negative = net cash)−15−3−2512−19−226−7−135−16
Shares outstanding9m———44m75m9m————

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AVTX vs CRDFAVTX vs CRVOAVTX vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Avalo Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Avalo Therapeutics, Inc.